Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. TB-500 is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Crush Research sell TB-500?
Crush Research has 2 COAs on file for TB-500 but no active price listing is currently tracked.
Is Crush Research's TB-500 third-party tested?
Yes — Disclosed Labs has indexed 2 Certificates of Analysis for Crush Research's TB-500, with the most recent showing 99.8% purity. Crush Research holds an overall trust grade of A (94/100) across all 105 COAs on file.
What is Crush Research's trust grade for TB-500?
Crush Research has an overall Disclosed Labs trust grade of A (94/100), computed from 105 COAs across all peptides. The most recent TB-500 COA was issued by BTLabs.
Where is the cheapest TB-500?
As of the latest data, Peptide Supply Co. offers TB-500 at $3.40/mg — compare with Crush Research's listing. See the full TB-500 price comparison.
Is TB-500 legal to buy?
TB-500 is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| View |